An Overview Of Pembrolizumab for High-Risk BCG Unresponsive NMIBC

Physician Summary:

Pembrolizumab (Keytruda)

• Mechanism of Action: Pembrolizumab is a PD-1 inhibitor that works by blocking the interaction between the PD-1 receptor on T cells and its ligands (PD-L1/PD-L2) on tumor cells. This enhances the immune system’s ability to recognize and attack cancer cells, particularly effective in treating carcinoma in situ and in cases with or without papillary tumors in BCG-unresponsive NMIBC.
• Administration: Unlike intravesical treatments, pembrolizumab is administered intravenously, typically every 3 weeks. This systemic approach allows it to target tumors throughout the body but requires careful monitoring for potential immune-related adverse effects.

Pembrolizumab offers a novel approach to managing high-risk, BCG-unresponsive NMIBC by harnessing the power of immunotherapy. Its ability to selectively block immune checkpoint signaling makes it effective in cases where traditional therapies fail.